AI주식인사이트AI Stock Insight
B

파마리서치

214450KOSDAQ

56.5 / 100

Reference Date: 2026-10-23

Financial Score28.0 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 22.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Parmaresearch is a biopharmaceutical company specializing in regenerative medicine, leveraging PDRN/PN technology to develop and sell pharmaceuticals, medical devices, and cosmetics. Established in 2013 with a GMP-certified factory in Gangneung and expanded with a second plant in 2019, the company's key products include Regenix, Rejuran, and Conjuuran. It plans to expand into Asian, European, and North American markets, while its subsidiary also operates a botulinum toxin business.

Number of Employees

526people

Average Salary

68.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
16.94Industry Average 15.003.0Point

Higher than industry avg (caution)

PBR
3.63Industry Average 1.200.0Point

3.0x industry avg (risky)

ROE
26.02Industry Average 8.007.0Point

3.3x industry avg (excellent)

Debt Ratio
28.95Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~202510.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲43.7% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲53.4% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 20.6% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 253,000Won52-week high 564,00052-week low 253,000
1-month return0.0Point

1m -22.75% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral주식등의대량보유상황보고서(약식)2026-10-02